Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.0 %

NYSE:BTX opened at $0.21 on Monday. The stock’s 50-day moving average is $1.80 and its 200-day moving average is $2.24. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The stock has a market cap of $12.07 million, a P/E ratio of -0.09 and a beta of 4.61.

Hedge Funds Weigh In On Brooklyn ImmunoTherapeutics

An institutional investor recently raised its position in Brooklyn ImmunoTherapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Brooklyn ImmunoTherapeutics Inc (NYSE:BTX) by 20.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,626 shares of the company’s stock after purchasing an additional 243,826 shares during the quarter. Renaissance Technologies LLC owned 2.48% of Brooklyn ImmunoTherapeutics worth $360,000 as of its most recent SEC filing. 26.00% of the stock is owned by institutional investors.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.